An Asia-Pacific perspective on resilience in the biopharma industry
An Asia-Pacific perspective on resilience in the biopharma industry 13 April 2021 | Analysis | By Ankit Kankar | ankit.kankar@mmactiv.com Preparing for the next pandemic means investing in our talent and people
Francis Van Parys, Vice-President Commercial, Asia-Pacific, Cytiva .
Countries in Asia-Pacific may have fared well in comparison to those in other areas of the world in coping with the current pandemic, but the region is performing below the global average when it comes to the resilience of the biopharma ecosystem according to our recently published Cytiva Global Biopharma Resilience Index.
The Index, which has been compiled in partnership with Financial Times company Longitude, tracks the resilience of the biopharma ecosystem in 20 countries by examining five areas of relevance: supply chain resilience, access to talent, strength of the R&D ecosystem, quality and agility of manufactu